The Nation Newspaper Internal Medicine Specialist warns of rare diabetes complication linked to SGLT2 inhibitors ...

OK, I know my gig is positivity and being upbeat and all that, but for today I thought I’d rant on about something that irks ...

General and administrative expenses (G&A) amounted to (€15.8) million for the fiscal year ended December 31, 2024, an ...

Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm ...

Adding CKD to the label for Jardiance (empagliflozin) adds to earlier approvals for type 2 diabetes and heart failure, and means that Boehringer and Lilly can now compete head to head across all ...

Pfizer, Merck & Co., Inc., UnitedHealth Group, Eli Lilly and Company, and AbbVie are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares in ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

The EMPACT-MI trial found that giving Boehringer Ingelheim and Eli Lilly’s SGLT2 drug Jardiance (empagliflozin ... in studies involving people with diabetes and kidney disease, and reduce ...

The U.S. equity market has had a solid run in the past two years, buoyed by a steadily improving macroeconomic environment ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...